 Muromonab-CD3
"Muromonab-CD3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).
| Descriptor ID |
D016853
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.570 D12.776.124.486.485.114.619.393.570 D12.776.124.790.651.114.224.075.570 D12.776.124.790.651.114.619.393.570 D12.776.377.715.548.114.224.284.570 D12.776.377.715.548.114.619.393.570
|
| Concept/Terms |
Muromonab-CD3- Muromonab-CD3
- Muromonab CD3
- Monoclonal Antibody OKT3
- OKT3
Orthoclone OKT3- Orthoclone OKT3
- Janssen Brand of Muromonab-CD3
- Janssen Brand of Muromonab CD3
- Ortho Brand of Muromonab-CD3
- Ortho Brand of Muromonab CD3
- Cilag Brand of Muromonab-CD3
- Cilag Brand of Muromonab CD3
|
Below are MeSH descriptors whose meaning is more general than "Muromonab-CD3".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Muromonab-CD3 [D12.776.124.486.485.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.486.485.114.619]
- Immunoglobulin G [D12.776.124.486.485.114.619.393]
- Muromonab-CD3 [D12.776.124.486.485.114.619.393.570]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Muromonab-CD3 [D12.776.124.790.651.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.790.651.114.619]
- Immunoglobulin G [D12.776.124.790.651.114.619.393]
- Muromonab-CD3 [D12.776.124.790.651.114.619.393.570]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Muromonab-CD3 [D12.776.377.715.548.114.224.284.570]
- Immunoglobulin Isotypes [D12.776.377.715.548.114.619]
- Immunoglobulin G [D12.776.377.715.548.114.619.393]
- Muromonab-CD3 [D12.776.377.715.548.114.619.393.570]
Below are MeSH descriptors whose meaning is more specific than "Muromonab-CD3".
This graph shows the total number of publications written about "Muromonab-CD3" by people in this website by year, and whether "Muromonab-CD3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 2 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1992 | 2 | 0 | 2 | | 1993 | 4 | 0 | 4 | | 1994 | 3 | 0 | 3 | | 1995 | 2 | 4 | 6 | | 1996 | 4 | 4 | 8 | | 1997 | 2 | 2 | 4 | | 1998 | 1 | 3 | 4 | | 1999 | 1 | 2 | 3 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Muromonab-CD3" by people in Profiles.
-
Oberholzer J, John E, Lumpaopong A, Testa G, Sankary HN, Briars L, Kraft KA, Knight PS, Verghese P, Benedetti E. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant. 2005 Aug; 9(4):456-63.
-
Farmer DG, McDiarmid SV, Edelstein S, Renz JF, Hisatake G, Cortina G, Fondevila C, Correa M, Rhodes S, Zafar A, Chavez Y, Yersiz H, Busuttil RW. Induction therapy with interleukin-2 receptor antagonist after intestinal transplantation is associated with reduced acute cellular rejection and improved renal function. Transplant Proc. 2004 Mar; 36(2):331-2.
-
Zielinski A, Nazarewski S, Bogetti D, Sileri P, Testa G, Sankary H, Benedetti E. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. Transplantation. 2003 Aug 15; 76(3):547-52.
-
Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13.
-
Brock MV, Borja MC, Ferber L, Orens JB, Anzcek RA, Krishnan J, Yang SC, Conte JV. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001 Dec; 20(12):1282-90.
-
Bond G, Reyes J, Mazariegos G, Wu T, Schaefer N, Demetris J, Fung JJ, Starzl TE, Abu-Elmagd K. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc. 2000 Sep; 32(6):1197-8.
-
Farrokh-Siar L, Rezai KA, Semnani RT, Patel SC, Ernest JT, van Seventer GA. Human fetal retinal pigment epithelium suppresses the activation of CD4(+) and CD8(+) T-cells. Graefes Arch Clin Exp Ophthalmol. 1999 Nov; 237(11):934-9.
-
Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
-
Onsager DR, Canver CC, Jahania MS, Welter D, Michalski M, Hoffman AM, Mentzer RM, Love RB. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant. 1999 May; 18(5):448-55.
-
Jordan ML, Shapiro R, Gritsch HA, Egidi F, Khanna A, Vivas CA, Scantlebury VP, Fung JJ, Starzl TE, Corry RJ. Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation. 1999 Jan 27; 67(2):266-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|